Albumin binding proteins and methods of use

Abstract

Provided herein are albumin binding proteins and methods of making and using thereof.

What is claimed is: 
     
         1 . A humanized albumin binding protein comprising: a VHH domain, the VHH domain comprising three complementarity determining regions (CDRs), CDR1, CDR2, and CDR3 therein, wherein:
 (a) the CDR1 has an amino acid sequence represented by SEQ ID NO: 104;   (b) the CDR2 has an amino acid sequence represented by SEQ ID NO: 109; and   (c) the CDR3 has an amino acid sequence represented by SEQ ID NO: 119.   
     
     
         2 . The humanized albumin binding protein of  claim 1 , wherein the VHH domain has an amino acid sequence comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 137-140. 
     
     
         3 . The humanized albumin binding protein of  claim 1 , further comprising an antigen represented by D2, wherein D2 is a binding protein or a non-antigen binding moiety, wherein D2 is linked to the humanized albumin binding protein of  claim 1  according to a formula, from N-to-C terminus represented by: (a) D1-L-D2, or (b) D2-L-D1, wherein L is a peptide linker and D1 is the humanized albumin binding protein of  claim 1 . 
     
     
         4 . The humanized albumin binding protein of  claim 3 , wherein the peptide linker has an amino acid sequence comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 58-73. 
     
     
         6 . The humanized albumin binding protein of  claim 3 , wherein D2 is selected from the group consisting of a single chain antibody or binding fragment thereof, an scFv, a bispecific scFv, a single heavy chain, a single light chain, a variable heavy-chain domain, a VHH, a variable light-chain domain, a variable NAR domain, a single chain polypeptide, a F(ab′), a F(ab′)2, a bi-specific F(ab′)2), a F(Ab′)3, a tri-specific F(Ab′) 3, an Fv, a DARPin, an Fc domain, an entire Fc, a modified Fc domain, an Fc domain with one or more substitutions relative to wild-type, an Fc fragment, a minibody, a diabody, a dAb fragment, an antibody, a monoclonal antibody, a multispecific binding protein, and a bispecific antibody. 
     
     
         7 . A humanized albumin binding protein comprising a VHH domain, wherein the VHH domain has an amino acid sequence comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 137-140. 
     
     
         8 . The humanized albumin binding protein of  claim 7 , further comprising an antigen represented by D2, wherein D2 is a binding protein or a non-antigen binding moiety, wherein D2 is linked to the humanized albumin binding protein of  claim 7  according to a formula, from N-to-C terminus represented by: (a) D1-L-D2, or (b) D2-L-D1, wherein L is a peptide linker and D1 is the humanized albumin binding protein of  claim 7 . 
     
     
         9 . The humanized albumin binding protein of  claim 8 , wherein the peptide linker has an amino acid sequence comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 58-73. 
     
     
         10 . The humanized albumin binding protein of  claim 8 , wherein D2 is selected from the group consisting of a single chain antibody or binding fragment thereof, an scFv, a bispecific scFv, a single heavy chain, a single light chain, a variable heavy-chain domain, a VHH, a variable light-chain domain, a variable NAR domain, a single chain polypeptide, a F(ab′), a F(ab′)2, a bi-specific F(ab′)2), a F(Ab′)3, a tri-specific F(Ab′)3, an Fv, a DARPin, an Fc domain, an entire Fc, a modified Fc domain, an Fc domain with one or more substitutions relative to wild-type, an Fc fragment, a minibody, a diabody, a dAb fragment, an antibody, a monoclonal antibody, a multispecific binding protein, and a bispecific antibody.